Business Context and Reporting Period
Healthcare Triangle, Inc. (HCTI), a Delaware corporation and emerging growth company, filed this Form 8-K on December 5, 2025. The report details the execution of a non-binding Advance Agreement with Teyame A.I. LLC regarding a proposed acquisition of two Spanish entities: Teyame 360 S.L. and Datono Mediacion S.L.
Key Financial Metrics and Transaction Terms
The filing outlines a proposed acquisition structure with a total consideration of up to approximately $50.0 million. The payment mix is structured as follows:
- Cash Consideration: Up to $15.0 million payable in tranches.
- Common Stock: Approximately $6.0 million in Company common stock.
- Convertible Preferred Stock (Post-Closing): Approximately $24.0 million, convertible six months after closing.
- Convertible Preferred Stock (Earnout): Approximately $5.0 million, subject to performance targets.
Liquidity and Immediate Cash Flow: The Company agreed to pay a $3.0 million cash advance to Teyame on or before December 8, 2025. This amount is intended to be credited against the final cash purchase price if the transaction closes.
Material Changes and Transaction Conditions
This filing represents a material strategic development rather than a change in historical financial performance. Key conditions include:
- Refund Provisions: If the transaction fails to close due to specified circumstances (e.g., failure to agree on terms, material adverse change, regulatory restrictions), Teyame must refund the full $3.0 million advance within ten business days.
- Delay Penalty: If the transaction fails to close by February 16, 2026, due to a delay attributable to the Company, Teyame must refund $2.5 million but may retain $500,000.
- Non-Binding Nature: The agreement does not obligate either party to consummate the acquisition. Closing is contingent upon the execution of a definitive share purchase agreement, due diligence, and potential stockholder approval.
Guidance, Outlook, and Risks
Outlook: The parties target a potential closing on or before February 16, 2026, subject to customary closing conditions.
Risks and Contingencies:
- The transaction is non-binding and may not be completed.
- Final purchase price and terms remain subject to negotiation.
- Regulatory or governmental restrictions could prevent closing.
- The $3.0 million advance is at risk of partial forfeiture ($500,000) if the Company causes a delay beyond the February 2026 deadline.
Financial Impact: The filing text does not provide clear values for the Company's current revenue, profit, cash flow, margins, or existing debt levels. The immediate financial impact is the commitment of $3.0 million in cash.
Investor Verification Checklist
- Verify the Company's current cash balance to assess the impact of the $3.0 million advance payment.
- Confirm the timeline for the execution of the definitive share purchase agreement.
- Monitor for any material adverse changes or regulatory hurdles that could trigger the refund of the advance.
- Review the specific performance targets required for the $5.0 million earnout component.
- Check for subsequent filings regarding stockholder approval requirements for the issuance of preferred stock.